ArticleScientific reports2026
A diagnostic stewardship bundle approach to facilitate same-day optimal antimicrobial therapy in gram-negative sepsis: a quasi-experimental study.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
It is challenging to reduce time to optimal antimicrobial therapy in patients with sepsis for microbiology laboratories in low to middle-income countries. We evaluated the diagnostic accuracy and impact of a diagnostic stewardship bundle titled "Sepsis-24" to reduce turnaround time (TAT) of provisional blood culture reports (pBCR) ≤ 24 h in patients with gram-negative bacteraemia. During the preintervention period (January-May 23), the key preanalytical and analytical parameters of automated blood culture diagnostics were optimized in a multiphasic manner. Early microbial identification and susceptibility testing were performed by direct inoculation of VITEK-2 identification cards from flagged blood culture bottles (+ BCs) and EUCAST RAST method, read at 8-hour. During the intervention period (June-December 2023), Sepsis-24 was implemented in adult ICUs to provide pBCR for four RAST reportable gram-negatives (RRGNs). The agreements of direct microbial identification and RAST for tested drug-bug combinations were 94% [95%CI: 90-98] and 93% [95%CI: 91-94], respectively during both periods. There was a statistically significant reduction in BC loading, unloading and performance of direct VITEK/RAST from + BC during intervention period [median (minutes): 32 versus 25, 12 versus 2, and 181 versus 70, p ≤ 0.001, respectively]. Of 49 pBCRs released, 48 (98%) were concordant in species-level microbial identification with a median TAT of 1473 min [IQR: 1635 - 1321], from sample receiving. Sepsis-24 facilitated early review of antimicrobial regimen in 71% (34/48) patients leading to therapy change in 64.7% (22/34) patients. Sepsis-24 was found to be diagnostically accurate and facilitated early review of antimicrobial therapy in our resource-limited setting.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.